We’ve created a new area on the project website for publications from our partners that are relevant to MErCuRIC – check it out!
EUPATI, the European Patients’ Academy on Therapeutic Innovation has published their Oct 2015 newsletter – learn more about the experience of students who have just completed the first Patient Xpert Training Course and why regulatory agencies think patient education and engagement are important.
In an IFOM interview, MErCuRIC researcher Prof. Alberto Bardelli of the Universita Degli Studi di Torino talks about why he studies colorectal cancer.
He describes personalised medicine, targeted therapies and resistance to therapy, as well as monitoring therapy in real time with blood-based assays called liquid biopsies.
You can watch the interview here.
MErCuRIC partners attended a successful meeting in VHIO, Barcelona on 16 Dec 2014. Progress made by the consortium in year 1 was discussed and work for year 2 was planned. To date, we have received ethical approval to open two sites (OXFORD and UZA) to recruit to the Phase I trial, and advanced the translational technologies to be implemented during the project.
We have new promotional material now available to view in our media area. Follow this link to view our latest flyer.
The NI Cancer Research Forum invite you to a free bowel cancer public information evening. Hear about new developments in Research and Care. Tuesday 2nd December 2014 Belfast City Hospital, Cancer Centre, Level 1, Seminar Room 3, 7-9pm
Refreshments will be served. Please contact if interested: firstname.lastname@example.org Tel: 028 90 638468
The MerCuRIC project was covered on UTV television’s UTV Live News programme and website on 11 December, including an interview with Prof Mark Lawler of QUB.
MErCuRIC is funded by the European Community’s Framework Programme Seven (FP7) under contract #602901. The material presented and views expressed here are the responsibility of the author(s) only. The EU Commission takes no responsibility for any use made of the information set out.